1. PI3K/Akt/mTOR
    Cell Cycle/DNA Damage
  2. PI3K


Cat. No.: HY-18085 Purity: 98.21%
Data Sheet SDS Handling Instructions

Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4-5.4 μM.

For research use only. We do not sell to patients.
Quercetin Chemical Structure

Quercetin Chemical Structure

CAS No. : 117-39-5

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
1 g $50 In-stock
5 g $80 In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References


Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4-5.4 μM.

IC50 & Target

IC50: 2.4-5.4 μM (PI3K)

In Vitro

Quercetin is a type of plant-based chemical, or phytochemical, used as an ingredient in supplements, beverages or foods. In several studies, it may have anti-inflammatory and antioxidant properties, and it is being investigated for a wide range of potential health benefits. Quercetin is a PI3K inhibitor with IC50 of 2.4-5.4 μM. It strongly abrogates PI3K and Src kinases, mildly inhibits Akt1/2, and slightly affected PKC, p38 and ERK1/2[1]. Quercetin inhibits TNF-induced LDH% release, EC-dependent neutrophils adhesion to bovine pulmonary artery endothelial cells (BPAEC), and BPAEC DNA synthesis and proliferation[2].

In Vivo

Combination of Quercetin (75 mg/kg) and 2-Methoxyestradiol enhances inhibition of human prostate cancer LNCaP and PC-3 cells xenograft tumor growth[3].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01708278 University of Michigan|National Institutes of Health (NIH)|Quercegen Pharmaceuticals|National Center for Complementary and Integrative Health (NCCIH) Chronic Obstructive Pulmonary Disease February 2014 Phase 1
NCT01376011 Brigham and Women's Hospital|National Institute on Aging (NIA) Stroke|Problem of Aging June 2009 Early Phase 1
NCT01720147 Children's Hospital Medical Center, Cincinnati Fanconi Anemia July 2012 Phase 1
NCT02226484 University of North Carolina, Chapel Hill|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Gastroesophageal Reflux Disease|GERD|Acid Reflux|Reflux August 2014 Phase 1
NCT01438320 University of California, Los Angeles|American Association for Cancer Research|Tower Cancer Research Foundation|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Chronic Hepatitis C July 2011 Phase 1
NCT00402623 Maastricht University Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development Sarcoidosis January 2006
NCT01691404 Wageningen University|Top Institute Food and Nutrition Hypertension|Endothelial Dysfunction September 2012
NCT01732393 Mashhad University of Medical Sciences Chemotherapy Induced Oral Mucositis January 2010 Phase 1|Phase 2
NCT01168739 University of New Mexico|Gatorade Sports and Science Institute|Quercegen Pharmaceuticals|Nash Finch Company Heat Acclimation and Thermotolerance September 2009
NCT01912820 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Adenocarcinoma of the Prostate|Recurrent Prostate Cancer|Stage I Prostate Cancer|Stage IIA Prostate Cancer|Stage IIB Prostate Cancer|Stage III Prostate Cancer|Stage IV Prostate Cancer January 2014 Phase 1
NCT01722669 Beth Israel Deaconess Medical Center Healthy May 2012 Early Phase 1
NCT01839344 Bastyr University Diabetes Mellitus, Type 2 May 2013 Phase 2
NCT01375101 Mashhad University of Medical Sciences Atrophic Oral Lichen Planus|Erosive Oral Lichen Planus April 2010 Phase 1
NCT01538316 University of Hohenheim|University Hospital Tuebingen|Quercegen Pharmaceuticals Primary Prevention of Prostate Cancer March 2012
NCT02989129 M.D. Anderson Cancer Center Polyneuropathies and Other Disorders of the Peripheral Nervous System|Chemotherapy Induced Neuropathic Pain July 2017 Early Phase 1
NCT00913081 University of Pennsylvania|Abbott Flushing February 2009 Phase 4
NCT01847521 Attikon Hospital Autism Spectrum Disorders December 2011 Phase 2
NCT01348204 University of Alabama at Birmingham|National Institutes of Health (NIH) Cystic Fibrosis March 2010 Phase 2
NCT02874989 Wake Forest University Health Sciences|Mayo Clinic Idiopathic Pulmonary Fibrosis (IPF) August 2016 Phase 1
NCT02848131 Mayo Clinic Chronic Kidney Disease July 2016 Phase 2
NCT02652052 Mayo Clinic Stem Cell Transplant March 2016
NCT00003365 University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey Colorectal Cancer August 1996
NCT02463357 University of Colorado, Denver|Alma College Mountain Sickness August 2015 Phase 4
NCT02866448 University of Reading|Biotechnology and Biological Sciences Research Council|Quercegen Pharmaceuticals Cardiovascular Disease August 2016
NCT02195232 Dana-Farber Cancer Institute|Quercegen Pharmaceuticals|National Heart, Lung, and Blood Institute (NHLBI) Thromboembolism of Vein VTE in Colorectal Cancer|Thromboembolism of Vein in Pancreatic Cancer|Thromboembolism of Vein in Non-small Cell Lung Cancer January 2015 Phase 2|Phase 3
NCT02446795 Consorzio Oncotech|Clinical Research Technology S.r.l.|Quercegen Pharmaceuticals Renal Cell Carcinoma|Kidney Cancer November 2016 Phase 1|Phase 2
NCT00455416 Oslo University Hospital|University of Oslo Follicular Lymphoma April 2007 Phase 2
View MoreCollapse
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 3.3086 mL 16.5431 mL 33.0863 mL
5 mM 0.6617 mL 3.3086 mL 6.6173 mL
10 mM 0.3309 mL 1.6543 mL 3.3086 mL
Animal Administration

Quercetin is formulated in 2-ME.

Mice are inoculated subcutaneously with 5×105 PC-3 cells suspended in 100μL PBS and 2×108 LNCaP cells suspended in 100μL of matrigel and PBS mixture (1:1) on the right back. When xenograft tumors reach a volume of approximately 100 mm3, mice are randomLy assigned to four groups (n=8 each group) and treated intraperitoneally. Therapeutic schedule based on our in vitro results, preliminary experiments and many other researchers' studies is as follows: (1) Vehicle control group: vehicle of quercetin on day 1, vehicle of 2-ME on day 2, (2) Quercetin treated group: quercetin 75 mg/kg on day 1, vehicle of 2-ME on day 2, (3) 2-ME treated group: vehicle of quercetin on day 1, 2-ME 150 mg/kg on day 2, (4) Combination treatment group: quercetin 75 mg/kg on day 1, 2-ME 150 mg/kg on day 2. Two days is a treatment cycle and the whole treatment process lasted for 4 weeks. Tumor sizes are monitored every 2 days using caliper and tumor volume are calculated according to the formula: L×S2×0.5, in which L represents the longest diameter and S represents the shortest diameter of tumor. Mice are weighed as well. At the end of treatment procedure, on day 29, mice are anesthetized with chloral hydrate and sacrificed by cervical dislocation. Xenograft tumors are taken out quickly and weighed. One part of it is put into liquid nitrogen immediately for future biomarker analysis and the other part is fixed in 10% neutral buffered formalin for immunohistochemical analysis. Serum biochemical parameters such as ALT, AST, creatinine and urea nitrogen that reflected drug toxicity are also detected. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight






Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 98.21%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: